Skip to main content
Top
Published in: Annals of Hematology 9/2016

01-09-2016 | Original Article

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis

Authors: Yu-Qing Pei, Yue Wu, Fei Wang, Wei Cui

Published in: Annals of Hematology | Issue 9/2016

Login to get access

Abstract

The understanding of genetic basis for Philadelphia-negative myeloproliferative neoplasm (MPN) has got much progress in recent years. But the effect of CALR vs. JAK2V617F mutations on the clinical progression and prognosis of primary fibrosis (PMF) remains relatively obscure. In this meta-analysis, we searched Pubmed, Embase, and Web of Science databases for observational studies published until February 2016. Researches that evaluated CALR vs. JAK2V617F mutations on PMF-relevant complications (splenomegaly, leukemic transformation, or thrombosis) and overall survival were selected. Pooled adjust odds ratio (OR), hazard risk (HR), and the corresponding 95 % confidence intervals (CI) were calculated for the CALR-mutant versus the JAK2-mutant categories. Twelve studies involving 435 CALR-mutated and 1116 JAK2V617F PMF patients were analyzed. CALR-mutated patients displayed a lower risk of splenomegaly (OR 0.47, 95 % CI 0.29–0.78) and thrombosis (OR 0.52, 95 % CI 0.29–0.92) but showed no significant difference in the risk of leukemic transformation (OR 0.90, 95 % CI 0.55–1.47) when compared with JAK2-mutated patients. CALR mutation favorably affected overall survival while JAK2 mutation led to poorer survival rate (HR 2.58, 95 % CI 2.08–3.20). This meta-analysis confirmed that a genetic classification of PMF by CALR and JAK2 mutations carried significant prognostic relevance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES et al (2008) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon Swerdlow SH, Campo E, Harris NL, Jaffe ES et al (2008) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon
2.
go back to reference Tefferi A (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(9):915–925CrossRefPubMed Tefferi A (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(9):915–925CrossRefPubMed
3.
go back to reference Reilly JT, McMullin MF, Beer PA et al (2012) Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 158(4):453–471CrossRefPubMed Reilly JT, McMullin MF, Beer PA et al (2012) Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 158(4):453–471CrossRefPubMed
4.
go back to reference Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790CrossRefPubMed Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790CrossRefPubMed
5.
go back to reference Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061CrossRefPubMed
6.
go back to reference Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397CrossRefPubMed Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397CrossRefPubMed
7.
go back to reference Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405CrossRefPubMedPubMedCentral Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405CrossRefPubMedPubMedCentral
8.
go back to reference Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390CrossRefPubMed Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390CrossRefPubMed
9.
go back to reference Yang Y, Wang X, Wang C et al (2015) A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia. Int J Hematol 101(2):165–172CrossRefPubMed Yang Y, Wang X, Wang C et al (2015) A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia. Int J Hematol 101(2):165–172CrossRefPubMed
10.
11.
go back to reference Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed
12.
15.
go back to reference Tefferi A, Lasho TL, Tischer A et al (2014) The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124(15):2465–2466CrossRefPubMedPubMedCentral Tefferi A, Lasho TL, Tischer A et al (2014) The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124(15):2465–2466CrossRefPubMedPubMedCentral
16.
go back to reference Tefferi A, Lasho TL, Finke C et al (2014) Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 28(7):1568–1570CrossRefPubMed Tefferi A, Lasho TL, Finke C et al (2014) Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 28(7):1568–1570CrossRefPubMed
17.
go back to reference Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477CrossRefPubMed Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477CrossRefPubMed
18.
go back to reference Kim BH, Cho YU, Bae MH et al (2015) JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. J Korean Med Sci 30(7):882–888CrossRefPubMedPubMedCentral Kim BH, Cho YU, Bae MH et al (2015) JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. J Korean Med Sci 30(7):882–888CrossRefPubMedPubMedCentral
19.
go back to reference Sazawal S, Singh N, Mahapatra M et al (2015) Calreticulin mutation profile in Indian patients with primary myelofibrosis. Hematology 20(10):567–570CrossRefPubMed Sazawal S, Singh N, Mahapatra M et al (2015) Calreticulin mutation profile in Indian patients with primary myelofibrosis. Hematology 20(10):567–570CrossRefPubMed
20.
go back to reference Kim SY, Im K, Park SN et al (2015) CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol 143(5):635–644CrossRefPubMed Kim SY, Im K, Park SN et al (2015) CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol 143(5):635–644CrossRefPubMed
21.
go back to reference Tefferi A, Guglielmelli P, Larson DR et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507–2513, quiz 2615CrossRefPubMedPubMedCentral Tefferi A, Guglielmelli P, Larson DR et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507–2513, quiz 2615CrossRefPubMedPubMedCentral
22.
go back to reference Qiao C, Sun C, Ouyang Y et al (2014) Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica 99(10):e182–e184CrossRefPubMedPubMedCentral Qiao C, Sun C, Ouyang Y et al (2014) Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica 99(10):e182–e184CrossRefPubMedPubMedCentral
24.
25.
go back to reference Andrikovics H, Krahling T, Balassa K et al (2014) Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica 99(7):1184–1190CrossRefPubMedPubMedCentral Andrikovics H, Krahling T, Balassa K et al (2014) Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica 99(7):1184–1190CrossRefPubMedPubMedCentral
26.
go back to reference Shirane S, Araki M, Morishita S et al (2015) JAK2, CALR, and MPL mutation spectrum in japanese patients with myeloproliferative neoplasms. Haematologica 100(2):e46–e48CrossRefPubMedPubMedCentral Shirane S, Araki M, Morishita S et al (2015) JAK2, CALR, and MPL mutation spectrum in japanese patients with myeloproliferative neoplasms. Haematologica 100(2):e46–e48CrossRefPubMedPubMedCentral
27.
go back to reference Guglielmelli P, Rotunno G, Fanelli T et al (2015) Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5(10):e360QCrossRef Guglielmelli P, Rotunno G, Fanelli T et al (2015) Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5(10):e360QCrossRef
28.
go back to reference Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901CrossRefPubMed Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901CrossRefPubMed
29.
go back to reference Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708CrossRefPubMed Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708CrossRefPubMed
30.
go back to reference Guglielmelli P, Nangalia J, Green AR et al (2014) CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol 89(5):453–456CrossRefPubMed Guglielmelli P, Nangalia J, Green AR et al (2014) CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol 89(5):453–456CrossRefPubMed
31.
go back to reference Shen HJ, Chao HY, Ding ZX et al (2015) CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leuk Lymphoma 56(3):820–822CrossRefPubMed Shen HJ, Chao HY, Ding ZX et al (2015) CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leuk Lymphoma 56(3):820–822CrossRefPubMed
32.
go back to reference Al Assaf C, Van Obbergh F, Billiet J et al (2015) Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 100(7):893–897CrossRefPubMedPubMedCentral Al Assaf C, Van Obbergh F, Billiet J et al (2015) Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 100(7):893–897CrossRefPubMedPubMedCentral
33.
go back to reference Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544–1551CrossRefPubMedPubMedCentral Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544–1551CrossRefPubMedPubMedCentral
34.
go back to reference Fu R, Xuan M, Zhou Y et al (2014) Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia 28(9):1912–1914CrossRefPubMed Fu R, Xuan M, Zhou Y et al (2014) Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia 28(9):1912–1914CrossRefPubMed
35.
go back to reference Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121–E124CrossRefPubMed Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121–E124CrossRefPubMed
36.
go back to reference Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861–1869CrossRefPubMed Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861–1869CrossRefPubMed
37.
go back to reference Guglielmelli P, Lasho TL, Rotunno G et al (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28(9):1804–1810CrossRefPubMed Guglielmelli P, Lasho TL, Rotunno G et al (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28(9):1804–1810CrossRefPubMed
Metadata
Title
Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis
Authors
Yu-Qing Pei
Yue Wu
Fei Wang
Wei Cui
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2712-0

Other articles of this Issue 9/2016

Annals of Hematology 9/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.